



8th November, 2019 | Rome, Italy
www.vitares.org

VITARES Research Institute
 via di Castel Romano 100, Rome

1st Therapeutic Antibody Workshop: along the path from Target Genes to Patients

The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. Therefore, Antibody generation and engineering is a growing area with lots of exciting developments and many clinical achievements.

The workshop will be held at the Conference Room c / o Tecnopolo - Building A (Third Floor)
 Via Castel Romano, 100 - 00128 Rome

PROGRAM:

- | | | | |
|-------|--|-------|--|
| 8.30 | Registration | 13.00 | Lunch Break & Networking |
| 9.00 | Basic principles of Antibodies, Angela Santoni ,
Università La Sapienza, Roma | 14.00 | Antibody Process Development,
Stefano Franceschini (IBI Lorenzini) |
| 9.30 | Learning from healthy controls and patients: the
strategy of human B cell memory development,
Rita Carsetti (Osp. Pediatrico Bambin Gesù, Rome) | 14.30 | GMP Production: Theoretical and practical aspects,
Valentina Flacca (Menarini Biotech) |
| 10.00 | Genetic vaccines and other tricks to generate great
monoclonal antibodies,
Giuseppe Roscilli (Takis Biotech, Rome) | 15.00 | Strategies of preclinical safety assessment of monoclonal
antibodies, Isabella Andreini (AkrosBioscience) |
| 10.30 | Phage Display Libraries, Christian Steinkühler (Exiris) | 15.30 | Experiences from a preclinical CRO in regulatory toxicity
study with monoclonal antibodies,
Laura Monetini (ERBC) |
| 11.00 | Coffee Break & networking | 16.00 | Clinical trials, program allocation e regulatory
challenges, Elizabeth Shields (MSD Italia) |
| 11.30 | Generating human antibodies in the mouse:
the Trianni platform, Gloria Esposito (Trianni) | 16.30 | Networking in Lazio (1): Rever3mab project,
Luigi Aurisicchio (Takis Biotech) |
| 12.00 | Synthetically engineered DNA-encoded monoclonal
antibodies (DMAbs): a new therapeutic strategy
for many diseases, Kevin Hollevoet , University of
Leuven | 17.00 | Networking in Lazio (2): The MenHub experience,
Leonardo Sibilio (Menarini Biotech) |
| 12.30 | Preclinical models for proof of concept studies,
Emanuele Marra /TBD (Takis Biotech) | 17.30 | Adjourn |

Sponsored by:

TRIANNI



MENARINI BIOTECH



ISTITUTO
BIOCHIMICO
ITALIANO
G. LORENZINI



info@vitares.org



associates@vitares.org



donate@vitares.org